Pediatric Leukemia: Immunotherapy and Precision Medicine Insights
A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Pediatric Hematology & Oncology".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 19
Special Issue Editors
Interests: cancer; pediatric oncology
Interests: anemia; clotting disorders; sickle cell disease; hemophilia; leukemia and lymphoma
Special Issue Information
Dear Colleagues,
Over the last 10 years, there have been significant advances in the field of pediatric leukemia and immunotherapy, including chimeric antigen receptor (CAR) T cell therapy, bispecific T cell engager antibody treatment, and the detection of measurable residual disease using next-generation sequencing methods. This Special Issue will provide a platform for laboratory investigators and clinical researchers to share their work on developing advanced, innovative diagnostic and therapeutic approaches with the potential to transform outcomes for children with high-risk leukemia. We are seeking contributions that highlight the development and clinical implementation of novel therapies, such as cellular therapies, targeted toward the disease itself or morbidities associated with treatments such as stem cell transplantation and targeted immunotherapies. We welcome reports of ongoing clinical trials and laboratory studies that shed light on emerging therapeutic strategies poised to shape the future of this field.
Dr. Irtiza N. Sheikh
Dr. Dristhi S. Ragoonanan
Dr. Amber Gibson
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- high-risk leukemia
- relapse
- cellular therapy
- immunotherapy
- stem cell transplantation
- adolescent and young adult
- CAR T cell therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
